Loading news...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Parkman Healthcare Partners initiated a 200,000-share stake in Masimo during the fourth quarter. The quarter-end position value rose by $26.01 million as a result.
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.
American Century Companies Inc. raised its holdings in shares of Masimo Corporation (NASDAQ: MASI) by 10.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 168,341 shares of the medical equipment provider's stock after acquiring an additional 16,113 shares
Tap five stocks, BJ, MCRI, CENT, SGHC and MASI, with increasing P/E ratios for an out-of-the-box approach.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Masimo (MASI). But which of these two stocks is more attractive to value investors?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MASI will be acquired by Danaher for $9.9B in cash, sending shares soaring as the medtech firm prepares to join DHR's Diagnostics segment.
The firm initiated a new position by purchasing about 1.6 million shares. It position equals 15.3% of the fund's 13F assets under management.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.
Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only partially offsets a period of long-term stagnation.
Masimo (MASI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Masimo Corporation (NASDAQ: MASI) related to its sale to Danaher Corporation.
Danaher has announced its plan to acquire Masimo (MASI) for $180 per share in an all-cash transaction. This represents a 38% premium over Masimo's previous clos